Tonix Pharmaceuticals to Participate in a Fireside Chat at the Cantor Global Healthcare Conference 2025GlobeNewsWire • 08/28/25
Tonix Pharmaceuticals Soars, Then Sinks: What's Next After Tonmya's Approval (Upgrade)Seeking Alpha • 08/19/25
Tonix Pharmaceuticals Announces FDA Approval of Tonmya™ (cyclobenzaprine HCl sublingual tablets) for the Treatment of FibromyalgiaGlobeNewsWire • 08/15/25
Tonix Pharmaceuticals Reports Second Quarter 2025 Financial Results and Operational HighlightsGlobeNewsWire • 08/11/25
Tonix Pharmaceuticals Announces the Launch of the “Move Fibro Forward” Campaign to Bring Awareness to Individuals Impacted by FibromyalgiaGlobeNewsWire • 07/21/25
Tonix Pharmaceuticals Announces Presentation of New Data on Mpox and Smallpox Vaccine Candidate TNX-801 at the Vaccine Congress 2025GlobeNewsWire • 07/10/25
Tonix Pharmaceuticals Announces On-line Publication of Phase 3 RESILIENT Trial Results of TNX-102 SL for Fibromyalgia in the Peer Reviewed Journal, Pain MedicineGlobeNewsWire • 07/09/25
Tonix Pharmaceuticals Announces Oral Presentation on Mpox and Smallpox vaccine candidate TNX-801 at the Vaccine Congress 2025GlobeNewsWire • 07/07/25
Tonix Pharmaceuticals Announces Peer-Reviewed Publication in Cancer Cell Journal Highlighting Positive Preclinical Data of mTNX-1700 in Gastric Cancer Animal ModelsGlobeNewsWire • 07/02/25
Tonix Pharmaceuticals Announces Inclusion in the Russell 3000® and Russell 2000® IndexesGlobeNewsWire • 06/30/25
Tonix Pharmaceuticals Presented Data and Analyses of TNX-102 SL Treatment Effects on Fibromyalgia at the Annual European Congress of Rheumatology (EULAR) 2025GlobeNewsWire • 06/16/25
Tonix Pharmaceuticals Announces Appointment of Commercial Industry Veteran, James “Jim” Hunter, to Board of DirectorsGlobeNewsWire • 06/13/25
Tonix Pharmaceuticals Announces Presentation at the 2025 BIO International ConventionGlobeNewsWire • 06/10/25
Tonix Pharmaceuticals Announces Poster Presentation at the Annual European Congress of Rheumatology (EULAR) 2025GlobeNewsWire • 06/05/25
Tonix Pharmaceuticals Announces Presentation at the A.G.P. Annual Healthcare Company ShowcaseGlobeNewsWire • 05/22/25
Tonix Pharmaceuticals Announces First Patient Dosed in Phase 2 OASIS Study of TNX-102 SL for Reduction of Acute Stress ReactionGlobeNewsWire • 05/21/25
Tonix Pharmaceuticals Announces Appointment of Joseph Hand, Esq., as General Counsel and Executive Vice President of OperationsGlobeNewsWire • 05/14/25
Tonix Pharmaceuticals Reports First Quarter 2025 Financial Results and Operational HighlightsGlobeNewsWire • 05/12/25
Tonix Pharmaceuticals Presented Preclinical Data on Gastric Cancer Models at the American Association for Cancer Research (AACR) 2025 Annual MeetingGlobeNewsWire • 04/29/25
Tonix Pharmaceuticals Presented Data on Potential Mpox Vaccine TNX-801 at World Vaccine Congress Washington 2025GlobeNewsWire • 04/24/25